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J.M. Schott et al. / Alzheimer’s & Dementia 12 (2016) 862-871 863Exploratory genome-wide association studies confirmed APOE and identified three novel loci:
rs76854344 near CNTNAP5 (P 5 8 ! 10210 OR 5 1.9 [1.5–2.3]); rs72907046 near FAM46A
(P 5 1 ! 1029 OR 5 3.2 [2.1–4.9]); and rs2525776 near SEMA3C (P 5 1 ! 1028, OR 5 3.3
[2.1–5.1]).
Discussion: We provide evidence for genetic risk factors specifically related to PCA. We identify
three candidate loci that, if replicated, may provide insights into selective vulnerability and pheno-
typic diversity in AD.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords: Posterior cortical atrophy; Alzheimer’s disease; Genetics; GWAS; Selective vulnerability; APOE1. Introduction
Posterior cortical atrophy (PCA) is a rare neurodegenera-
tive syndrome, typically a variant of Alzheimer’s disease
(AD), although occasionally due to other pathologies
including dementia with Lewy bodies, corticobasal degener-
ation, and prion disease [1]. Patients with PCA present with
combinations of cognitive problems attributable to posterior
cortical dysfunction and in particular difficulties with higher
level visual processing including simultanagnosia, optic
apraxia, optic ataxia, and visual disorientation; other fea-
tures may include dyslexia, dyscalculia, dysgraphia, and
limb dyspraxia. In contrast with typical, amnestic AD, mem-
ory is relatively spared until the disease becomes advanced.
MR brain imaging in PCA typically shows parieto-occipital
lobe atrophy with relative preservation of medial temporal
lobe structures [2]; fluoro-deoxyglucose positron emission
tomography (PET) shows prominent posterior cortical hypo-
metabolism [3]; and in a single case study using the AV1451
tau PET tracer, posterior cortical tau deposition [4]. By
contrast, PET imaging using amyloid-binding ligands typi-
cally shows global amyloid deposition [3]. Aside from the
imaging and cognitive differences, patients with PCA are
typically younger than those with typical amnestic late-
onset AD, usually with disease onset in the sixth or seventh
decade [1]. PCA is almost invariably a sporadic disorder, and
the risk factors for developing the syndrome are unknown.
Understanding the genetic architecture of the PCA variant
of AD may provide insights both into factors predisposing
to young onset AD, as well as mechanisms underlying
regional vulnerability in AD.
To date, only a few, single-center studies have addressed
genetic risk for PCA [5–10], and due to the rarity of the
syndrome all have been relatively small, the largest being
a maximum of 81 cases [9]. Some, but not all, of these
studies have suggested that despite their early-disease onset,
patients with PCA may be less likely than expected to have
an APOE ε4 allele, the commonest risk factor for late-onset
AD. Other studies have suggested that there may be differ-
ences in some of the more recently identified genetic risks
for AD in patients with PCA [9]. Recognizing the rarity of
this AD variant, we formed an international consortium
comprising eleven centers, using clinical diagnostic criteriato define cases of PCA, with the principal aim of determining
whether APOE ε4 and genetic risks from recent genome-
wide association studies (GWAS) of AD and dementia
with Lewy bodies (DLB, see below) are risk factors for the
PCA variant of AD. In a second, exploratory analysis, we
performed a pilot GWAS analysis to identify novel putative
genetic risk factors for PCA.2. Methods
2.1. PCA patients and controls
After an inaugural multidisciplinary meeting of PCA re-
searchers [11], latterly formalized as the Alzheimer’s Asso-
ciation’s International Society to Advance Alzheimer’s
Research and Treatment (ISTAART) Professional Interest
Area in Atypical AD and Associated Syndromes, an interna-
tional collaborative group was established to assess genetic
risk factors for PCA. Researchers identified individuals
with PCA, in whom a deoxyribo nucleic acid (DNA) sample
was available. Patients who the referring physician had diag-
nosed with AD, had multidomain cognitive impairment ful-
filling criteria for AD dementia, and had one or both of two
published criteria for PCA, as proposed by Tang-Wai [5] and
Mendez [12] (Table 1) were included. Additional data
collected included gender, age at disease onset, age at death
(where applicable), and whether there was molecular (cere-
brospinal fluid or amyloid PET using locally defined ranges)
evidence or pathologic confirmation of underlying AD pa-
thology. Each site had appropriate local ethical approvals
in place, and all participants gave informed written consent.
Controls were from UK, USA, and Germany (see below).2.2. Genetic and statistical analyses
DNA samples were analyzed at the MRC Prion Unit,
Department of Neurodegenerative Disease, Institute of
Neurology, UCL. PCA samples were genotyped on Illumina
660 arrays (n5 54, UCL cohort only) and OmniExpress ar-
rays (n5 239, all cohorts); in total, 293 passed sample qual-
ity control, implemented using PLINK. Controls were
genotyped on Illumina 550 (n 5 809, KORA F4 German,
PMID: 16032514), OmniExpress (n 5 1185, Geisinger US
Table 1
Clinical criteria for PCA
Tang-Wai et al, 2004 [5] Mendez et al, 2002 [11]
Core features
Insidious onset and gradual progression
Presentation of visual complaints in the absence of significant
primary ocular disease
Relative preservation of anterograde memory and insight early in the
disorder
Disabling visual impairment throughout the disorder
Absence of stroke or tumor
Absence of early parkinsonism and hallucinations
Any of the following findings
Simultanagnosia with or without optic ataxia or ocular apraxia
Constructional dyspraxia
Visual field defect
Environmental disorientation
Any of the elements of Gerstmann syndrome
Supportive features
Alexia
Presenile onset
Ideomotor or dressing apraxia
Prosopagnosia
Investigations
Neuropsychological deficits referable to parietal and/or occipital
regions
Focal or asymmetric atrophy in parietal and/or
occipital regions on structural imaging
Focal or asymmetric hypoperfusion/hypometabolism in parietal and/
or occipital regions on functional
imaging.
Core diagnostic features (all must be present)
Insidious onset and gradual progression
Presentation with visual complaints with intact primary visual
functions
Evidence of predominant complex visual disorder on examination
Elements of Balint’s syndrome
Visual agnosia
Dressing apraxia
Environmental disorientation
Proportionally less impaired deficits in memory and verbal fluency
Relatively preserved insight with or without depression
Supportive diagnostic features
Presenile onset
Alexia
Elements of Gerstmann’s syndrome
Ideomotor apraxia
Physical examination within normal limits
Investigations
Neuropsychology: predominantly impaired perceptual deficits
Brain imaging: predominantly occipitoparietal
abnormality (especially on functional neuroimaging) with relative
sparing of frontal and mesiotemporal
regions.
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KORA F3 German), Illumina 5M (n 5 1651, Framingham
US, see acknowledgments), and Illumina 1.2 M
(n 5 5020, WTCCC2 UK, see acknowledgments) arrays.
Physical locations refer to the Feb 2009 (GRCh37/hg19) as-
sembly. We excluded SNPs with a minor allele frequency
(MAF) , 1% (n 5 70,042 from OmniExpress case arrays);
genotyping rate,99% (n5 85,086 from OmniExpress case
arrays); or Hardy-Weinberg Equilibrium (HWE) exact test
P , 1023 in controls. Cases with call rate ,98% (n 5 6)
as well as ethnic outliers (n5 2) were excluded after visual-
ization of multidimensional scaling plots. Related and dupli-
cate cases were removed by IBS/IBD calculation (n5 1) and
re-examination of patient data, as they became available post
genotyping (n 5 2). A Pi-Hat (proportion identity by
descent) threshold of .0.1875 was used, which should
exclude first and second degree relatives. Two duplicates
removed due to later availability of patient data were also
included within the six cases removed for low call rate
thus bringing the total number of cases removed to nine.
Owing to the multitude of different genotyping platforms,
control comparisons were carried out sequentially and ex-
clusions removed at each stage. A total of 840 KORAF4
German controls were originally genotyped; 17 with call
rate ,98%, six with Pi-Hat . 0.1875 and eight MDS out-
liers were removed. A total of 1950 KORAF3 German con-
trols were originally downloaded; threewith call rate,98%,57 with Pi-Hat . 0.1875, and eight MDS outliers were
removed. A total of 1264 Geisinger US controls were origi-
nally downloaded; two with call rate ,98%, 69 with Pi-Hat
.0.1875, and eight MDS outliers were removed. 2467 FHS
US controls were originally downloaded; 16 with call rate
,98%, 793 with Pi-Hat .0.1875 and seven MDS outliers
were removed. 5050 WTCCC2 UK controls were generated
from available raw IDAT files; 26 with call rate,98%, four
with Pi-Hat. 0.1875, and zero MDS outliers were removed
(see Supplementary Table 1). All remaining cases and
controls were finally visualized on an MDS plot (see
Supplementary Fig. 1), outlier detection was performed us-
ing PLINK v1.07, and no further outliers were detected. IBS/
IBD estimation of the final cases and controls also lead to no
further exclusions based on relatedness. Shapeitv2 was used,
in conjunction with the 1000 Genomes Phase 1 Integrated
variant set (b37 March 2012 release), to align all data rela-
tive to the positive strand [13]. To avoid potential down-
stream cross platform confusion, however, we removed
any A/T or G/C transversions to phase each chromosome
from each platform separately before imputation using
Impute2 (v2.3.0). GTOOL (v0.6.6) was used to extract and
collate samples into their respective cohorts for association
testing [14]. Association testing was performed using
SNPtest_v2.5-beta4 employing the frequentist (additive
model) score method which involves weighting by the likeli-
hood of each imputed genotype [15]. Four population
Table 2
Clinical features and demographics
Total number of DNA samples received 302
Number (%) male 124 (41%)
Mean 6 SD age at onset (y) 58.9 6 6.9
Number (%) with young onset dementia (onset ,65 y) 249 (83%)
Number with biomarker/path evidence for AD* 82 (27%)
Number (%) with known age of death 34
Mean 6 SD age at death (y) 67.9 6 7.7
9 samples failed genetic QC
Total number of DNA samples passing QC and entering
analysis
293
Number (%) male 120 (41%)
Mean 6 SD age at onset (y) 58.8 6 6.9
Number (%) with young onset dementia (onset ,65 y) 243 (83%)
Number with biomarker/path evidence for AD* 77 (26%)
Number (%) with known age of death 33
Mean 6 SD age at death (y) 67.8 6 7.8
*No individual with biomarker/path evidence for a non-AD diagnosis
was included.
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used in the association analysis [16,17]. The case-control as-
sociation test statistic inflation factor was 1.06
(Supplementary Fig. 2). Any association statistics
mentioned in the results section are shown with standard
genomic control (PGC) corrected and uncorrected P values.
Post association-testing QC excluded markers with a MAF
,1% and departure from HWE, in both combined and any
single control cohort P , 1024. We also excluded markers
with a SNPtestv2 derived “info metric” and “add info
metric” below 0.9. The final autosomal analysis thus
included 5.9 M markers.
We assessed whether the genetic risks for typical AD
and PCA were different by comparing odds ratios (OR)
between our study and those published in typical AD
[18]. We employed a Wald-type test, first calculating the
standard error of the difference in log (OR) from the re-
ported CIs. We then divided the empirical difference in
log (OR) by its standard error, and thus derived a z-score
and P value, relying on the approximate normality of log
(OR) estimates from large samples. In the main analysis
of candidate SNPs, we used a Bonferroni corrected asso-
ciation threshold of P , .002 based on the testing of a lead
SNP from 24 independent loci derived from studies of AD
[18] and DLB [19].
Although the typical samples sizes that are required to
discover novel genome-wide significant risk factors in
complex disorders are in the thousands, there are some
precedents of strong genetic effects detected with small
but phenotypically homogenous samples, including vari-
ants at APOE in AD [20], PRNP in prion disease [21],
and complement factor H in age related macular degener-
ation [22]. We therefore performed an exploratory
genome-wide association study using established method-
ologies that account for population structure and with
imputation of SNPs not present on the genotyping arrays.
As PCA is a clinical syndrome that may be due to pathol-
ogies other than AD, we also assessed the odds ratios at
SNPs of interest in a subset of patients with biomarker/
pathological evidence for AD.
3. Results
3.1. Patients and demographics
A total of 302 samples fulfilling entry criteria to the study
were available from eleven centers: University College
London (n 5 94); Mayo Clinic, USA (n 5 77); University
ofCalifornia SanFrancisco,USA (n5 25);University of Sev-
ille, Spain (n5 25); University of Manchester, UK (n5 20);
VUUniversity,Netherlands (n5 17);University ofCalifornia
SanDiego,USA (n5 16); INSERM,France (n5 10);Univer-
sity of Milan, Italy (n5 6); CHU Besanc¸on, France (n5 6);
andUniversity ofNewSouthWales, Australia (n5 6).Demo-
graphics are shown in Table 2. All samples fulfilled Tang-Wai
clinical criteria for PCA [5], and in the 225 samples for which
datawere available, 97.3% also fulfilledMendez criteria [12];41% of the cohort was male. Mean (6SD) age at symptom
onset was 58.9 6 6.9 years, and 82.5% had young onset de-
mentia, as defined by age at onset of ,65 years. Thirty-four
patients had died, with a mean age at death of 68.0 (67.7)
years. Molecular or pathologic evidence for underlying Alz-
heimer pathology was available for 82 (27%), of whom 52
had a CSF profile compatible with AD; 32 had a positive am-
yloid PET scan; and 15 had autopsy proven AD. None had
evidence for pathology or biomarkers for non-AD pathology.
DNA from nine individuals failed array quality control,
and statistical analyses were done on the remaining 293/
302 samples (see Table 2). We also considered the associa-
tions in the sub-sample of 82 with biomarker/autopsy
evidence for underlying AD pathology.
3.2. Comparisons at known genetic loci for AD and DLB
Results of the genetic analysis of candidate risk factors for
the whole PCA cohort are shown in Table 2. First, we consid-
ered 24 SNPs known to be genetic risk factors in AD and/or
DLB. The best proxy genotyped for the APOE ε4 AD-risk
allele, rs2075650, located on chromosome 19 in the
TOMM40 gene and 13kb upstream of APOE, was identified
as a strong risk factor for PCA (OR 2.03, [95% CI 5 1.68–
2.46], P 5 6 ! 10214, PGC 5 3 ! 10
213; Fig. 1 and
Fig. 2A). rs3818361 located on chromosome 1 in CR1 was
also significantly associated (ORs 5 1.38 [1.14–1.67],
P 5 7 ! 1024, PGC 5 1 ! 10
23; Fig. 2B). rs3764650 in
ABCA7 (OR 5 1.39 [1.07–1.8], P 5 .02, PGC 5 .02) and
Fig. 1. Manhattan plot of autosomes with the threshold for genome-wide significance (P, 5! 1028) indicated by the red line. Four loci achieved statistical
significance at APOE (chromosome 19), SEMA3C (chromosome 7), FAM46A (chromosome 6), and CNTNAP5 (chromosome 2).
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PGC5 .05) reached nominal significance but did not surpass
our Bonferroni corrected threshold of P, .002. Other candi-
date SNPs showed no evidence of association.
In the subset of individuals with either biomarker (CSF or
amyloid PET) or pathologic evidence for underlying AD
(n 5 82), rs2075650 (at the APOE/TOMM40 locus, subse-
quently referred to as APOE) was again identified as a riskFig. 2. SNP annotation and proxy (SNAP) plots for five regions of interest showing
GWAS (A,C,D,E). These plots illustrate the statistical evidence of association at a
rium between the most strongly associated SNP and its neighbors on the chromosfactor with a similar OR to the whole group (OR 5 2.00
[1.39–2.89] P 5 9 ! 1025, PGC 5 1 ! 10
24). rs3818361
(CR1) and rs3764650 (ABCA7) both showed nominally sig-
nificant differences compared with controls (CR1 OR5 1.7
[1.20–2.41], P 5 .003, PGC 5 .004; ABCA7 OR 5 1.83
[1.17–2.86], P 5 .009, PGC 5 .01). There was no evidence
for an effect of BIN1 (OR 5 1.08 [0.76–1.52], P 5 .65) in
the biomarker cohort.significance in either known genetic loci for AD (A, B) or in the exploratory
locus together with information about nearby genes and linkage disequilib-
ome.
Table 3
Results of themain analysis for candidate SNPswhich were discovered in typical AD (ref [16], except *Seshadri et al. JAMA 2010:303; 1832–40, yHollingworth
et al. Nat Genet 2011:43:429–35) or DLB [17]
Candidate SNP Chr Nearest gene
Typical
AD/DLB OR
PCAvs control
P value PCAOR PCAOR CI
P Value for comparison
of OR (PCAvs typical AD)
Cases
MAF
Control
MAF
rs3818361 1 CR1 1.17 6.71E204 1.38 (1.14–1.67) .09 0.24 0.19
rs744373 2 BIN1 1.17 0.04 1.20 (1.01–1.43) .77 0.32 0.28
rs35349669 2 INPP5D 1.08 0.21 0.89 (0.75–1.04) .02 0.46 0.49
rs6825004 4 SCARB2 0.78 0.42 0.92 (0.77–1.1) .38 0.29 0.31
rs7687945 4 SNCA 0.75 0.92 1.00 (0.85–1.18) .08 0.49 0.49
rs190982 5 MEF2C 0.93 0.66 0.99 (0.83–1.18) .50 0.40 0.40
rs10948363 6 CD2AP 1.10 0.67 0.97 (0.8–1.17) .19 0.27 0.27
rs11767557 7 EPHA1 0.90 0.39 0.92 (0.74–1.13) .73 0.19 0.20
rs2718058 7 NME8 0.93 0.17 1.12 (0.95–1.33) .03 0.39 0.36
rs1476679 7 ZCWPW1 0.91 0.73 1.05 (0.88–1.25) .12 0.31 0.30
rs11136000 8 CLU 0.87 0.27 0.91 (0.77–1.09) .58 0.37 0.40
rs28834970 8 PTK2B 1.10 0.27 1.10 (0.93–1.3) .98 0.37 0.35
rs10838725 11 CELF1 1.08 0.98 1.01 (0.84–1.2) .45 0.32 0.31
rs670139y 11 MS4A4E 1.08 0.77 0.97 (0.82–1.14) .19 0.40 0.41
rs983392 11 MS4A6A 0.90 0.71 1.04 (0.88–1.22) .09 0.42 0.41
rs3851179 11 PICALM 0.87 0.39 0.94 (0.79–1.11) .40 0.35 0.37
rs11218343 11 SORL1 0.77 0.57 0.81 (0.4–1.65) .88 0.01 0.02
rs17125944 14 FERMT2 1.14 0.73 0.94 (0.7–1.27) .21 0.08 0.09
rs10498633 14 SLC24A4
RIN3
0.91 0.14 0.86 (0.7–1.06) .62 0.20 0.23
rs3764650 19 ABCA7 1.20 0.02 1.39 (1.07–1.8) .28 0.12 0.09
rs2075650 19 APOE 2.83 6.24E214 2.03 (1.68–2.46) .0007 0.25 0.14
rs3865444y 19 CD33 0.91 0.69 0.95 (0.8–1.14) .61 0.30 0.31
rs597668* 19 EXOC3L2
BLOC1S3
MARK4
1.18 0.59 1.04 (0.84–1.3) .30 0.17 0.16
rs7274581 20 CASS4 0.88 0.52 1.12 (0.85–1.48) .09 0.10 0.09
OR, odds ratio; MAF, minor allele frequency; CI, confidence interval.
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Comparing odds ratios and the nominal risk conferred in
the whole PCA cohort against the most recently published
mega-meta studies of typical AD [16], the effect size seen
at the APOE locus was significantly less strong in PCA
than for typical AD (PCA: OR 2.03, typical AD: OR 2.83,
P 5 .0007, PGC 5 .001, see methods). Although there was
no evidence for risk in PCA vs controls, the risk effects at
rs35349669 in INPP5D (P 5 .02, PGC 5 .02) and
rs2718058 upstream of NME8 (P 5 .03, PGC 5 .04) both
were nominally different in PCA than typical AD.
3.4. Exploratory GWAS
As several different array platformswere used in the study,
only 210,670 SNPswere genotyped across all samples. In this
set, therewas little evidence of inflation in the association test
statistic (l5 1.05). Only the proxy for the APOE ε4 AD-risk
allele, rs2075650, achieved genome-wide significance. We
went on to analyze 5.9-M SNPs in the imputed data set. Aside
from chromosome 19 (APOE locus), three loci on chromo-
somes 7, 2, and 6 respectively were of interest (Fig. 1).
rs2525776 on chromosome 7, upstream of SEMA3C (OR
3.3 [2.1–5.1], P 5 1.4 ! 1028, PGC 5 4 ! 10
28;
Fig. 2C); rs76854344 on chromosome 2, upstream of
CNTNAP5, (OR 1.9 [1.5–2.3], P 5 8.0! 10210, PGC 5 2! 1029; Fig. 2D), and rs72907046 on chromosome 6, down-
stream of FAM46A (OR 3.2 [2.1–4.9], P 5 1.1 ! 1029,
PGC5 3! 10
29; Fig. 2E) were all associated with PCA. Re-
stricting the analysis to the 82 individuals with biomarker/pa-
thology evidence for underlying AD pathology, the
corresponding odds ratios were similar: 3.8 [1.8–8.2],
P 5 2.8 ! 1024 for rs2525776; 1.8 [1.2–2.7], P 5 2.1 !
1023 for rs76854344; and 2.5 [1.0–6.1], P 5 2.7 ! 1022
for rs72907046. None of these three loci showed any evi-
dence of association with typical AD on the IGAP AD-risk
GWAS meta-analysis. A full list of suggestive associations
P, 1024 based on the SNPs represented on case and control
arrays (the intersection SNPs) is available in a Supplementary
Table 2, and summary statistics from the entire data set is
available at the NHGRI-EBI GWAS Catalog.4. Discussion
We report findings from a consortium to study genetic
risk factors in PCA, a rare predominantly early-onset cogni-
tive disorder characterized by progressive and dispropor-
tionately posterior cortical dysfunction and atrophy, and
usually associated with AD-type pathology. Our primary
aim was to explore the relationship between PCA and a pre-
determined list of candidate SNPs derived from studies of
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tion of genetic risk for PCA at some of the known AD-risk
loci, but not at the two DLB-risk loci that were tested
(Table 3). We demonstrate PCA-risk association with vari-
ants in or near APOE, CR1, ABCA7 and BIN1 in the whole
cohort, but only those at APOE, CR1, and ABCA7 remain
nominally significant in the small molecularly defined sub-
group. We also show evidence for nonoverlapping CIs of ge-
netic risk at APOE, INPP5D, and NME8. Although this is by
far the largest study of PCA to date, our relatively small sam-
ple size remains underpowered to detect genome-wide
significant associations at risk loci with small effect sizes,
such as those shown to associate in AD-risk GWAS. Howev-
er, our exploratory GWAS nominates the three novel loci,
SEMA3C, CNTNAP5, and FAM46A, which achieved
genome-wide significance, as potential genes of interest in
PCA.
Although still small for genetic studies, this collection is
the result of a global collaborative effort and is considerably
larger than any previous studies of PCA reporting varying
evidence that APOE is a risk factor [5–10]. Although the
vast majority of samples in previous studies overlap with
the present study, individual studies comprise ,w25% of
the current total. We found robust genetic association at
APOE but with an odds ratio significantly smaller than
those seen in typical AD. APOE is the best established and
strongest risk factor for sporadic AD and has been
associated not only with increased risk per se, but also
with earlier disease onset [23], the rate of hippocampal atro-
phy [24] and more memory led disease. However, the situa-
tion is more complex in early-onset AD which is associated
both with a greater proportion of nonamnestic presentations,
and perhaps a relatively reduced proportion of APOE ε4 car-
riers [25]. Studies investigating APOE risk for PCA (or as it
was sometimes previously defined, biparietal AD [6]), have
shown mixed results, perhaps due to differences in case defi-
nition, and the limited sample size of each study. In this
study of PCA, by far the largest yet published, we confirm
that APOE is a risk factor for PCA, but that it is a weaker
risk factor than for typical AD.
Addressing risk factors other than APOE, the largest sin-
gle previous study—which included samples also used in
this analysis—found nominally significant association with
SNPs in or near CLU, BIN1, and ABCA7 [9]. We found ev-
idence of association in the same direction for the SNP at
ABCA7 both in the whole cohort and those with biomarker
evidence for AD; for BIN1 in the whole cohort alone; but
could not confirm that SNPs near to CLU are risk factors.
Aside from APOE, only variants inCR1 surpassed our statis-
tical threshold for multiple testing in the whole cohort; these
variants also showed nominal significance in the biomarker
positive subgroup. Estimates of effect size were greater in
PCA than those in typical AD at each associated locus aside
from APOE. Although these differences were only nomi-
nally statistically significant, the four risk loci we report
are among the strongest known common genetic risk factorsfor typical AD (Table 3). CR1 has multiple functions
including the regulation of complement and phagocytosis
of immune complexes and pathogens, which are increas-
ingly though to be relevant to AD pathogenesis [26].
ABCA7 may play a role in AD through regulation of phago-
cytosis or lipid metabolism. BIN1mechanisms in AD are un-
clear but may be involved in endocytosis and the recycling of
endocytic vesicles [27].
Although they did not confer significant alteration of
PCA risk, we found that odds ratio confidence intervals for
SNPs at or near to INPP5D and NME8 in PCA did not over-
lap those of typical AD and showed directionally opposite
effects, INPP5D was identified as a risk factor for AD in a
recent large meta-analysis and plays an important role in a
number of inflammatory processes. There is little evidence
for the function of NME8 in the central nervous system,
although a role in modification of oxidative stress has been
proposed [28]. Although these findings were only nominally
significant and need independent replication, they do raise
the possibility that syndromic variants of AD may be differ-
entially associated with alterations in certain risk genes,
perhaps through altered responses to inflammation or stress.
The results of our exploratory genome-wide study impli-
cate three potential strong risk loci, near to CNTNAP5,
FAM46A, and upstream of SEMA3C. The regions of strong
LD with these associations did not include directly geno-
typed SNPs across all platforms, and therefore false-
positive associations related to differential accuracy of
imputation between case and control arm of the study remain
possible. With the caveat that these findings must therefore
be considered preliminary and require follow-up replication
in an independent sample and by direct genotyping, it is
notable that all three genes have roles in processes poten-
tially relevant to PCA. Contactin-associated protein-like 5
gene (CNTNAP5) belongs to a subgroup of the neurexin
family of multidomain transmembrane proteins involved in
cell adhesion and intercellular communication in the central
nervous system and has been implicated as a risk factor for
bipolar disorder and autism spectrum disorders [29]. Family
with sequence similarity 46, member A1 (FAM46A), origi-
nally C6orf37, is preferentially expressed within the neural
retina [30] and has been implicated in cell signaling path-
ways related to retinal neurodegeneration [31]. Class III
semaphorins including Semaphorin 3C (SEMA3C) have
been examined as potential modifying factors in neurode-
generation through interactions with plexins and neuropi-
lins. SEMA3C has been identified as a chemotrophic
molecule influencing attractive guidance for cortical axon
development [32]; the expression of SEMA3C and its recep-
tors have been shown to influence the maturation of the vi-
sual system [33]; and SEMA3C is also expressed in the
hippocampus, where it has a role in influencing the afferent
connections of the developing hippocampus and in partic-
ular the ingrowth of septo-hippocampal connections [34],
the major cholinergic connections implicated in learning
and memory [35]. Finally, SEMA3C expression has been
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within the brain [36]. Although at this stage speculative, it
is possible therefore that perhaps subtle differences in
cortical development might influence where pathology starts
and/or how it spreads through the brain if a neurodegenera-
tion process is initiated later in life. The fact that all three of
these novel genetic risks showed nominal associations in the
relatively small subset of individuals with biomarker evi-
dence for AD and the absence of similar evidence of associ-
ation in any of these genes with IGAP studies of typical AD
suggest that if confirmed, these loci may be specific risks for
PCA due to Alzheimer’s disease.
The main limitation of our study is the necessarily
modest sample size of this very rare disorder, noting that
the case numbers presented here were only achievable
through the establishment of an international consortium.
We plan to continue to collect further samples to allow
for replication in due course. Based on standard power cal-
culations in case-control studies, even in the favorable sit-
uation of completely accurate imputation of the functional
SNP we are only adequately powered to detect effect sizes
of OR .1.5, for common candidate SNPs, and the only
common genetic risk factor of this strength in typical AD
is APOE. We made comparisons with studies of patients
diagnosed with typical AD; however, these patients
and/or studies are different in multiple ways including
the genotyping platforms used, later age at clinical onset,
potential pathologic heterogeneity, and most probably dif-
ferences in geographical location, all of which could
confound the comparison. Although PCA is underpinned
by AD pathology in most cases, we only had evidence
for underlying AD in a proportion (w1/4), and we cannot
confirm that the genetic risks we have determined are spe-
cific for the AD variant of PCA rather than the syndrome of
PCA or for young onset AD. However, allowing for the
fact that the confidence intervals are inevitably large, it is
notable that the estimates for the odds ratios for APOE,
CR1, and ABCA7, and the putative genes identified in our
exploratory GWAS were similar or larger in the proportion
with molecular evidence for AD, suggesting that the risk
we identify are likely to be for the AD variant of PCA,
rather than for the syndrome per se.
One of the major outstanding issues in neurodegenerative
disease research is an explanation for the often very striking
phenotypic heterogeneity underpinned by the same broad
core pathology. Possibilities for phenotype modification
include demographic and environmental factors, including
age at onset, or perhaps more likely complex gene and/or
environment interactions and/or factors related to the mis-
folded proteins and their propagation, tissue or network
selectivity and toxicity. The results of this study suggest
that subtle differences in established risk factors may be
associated with some of this heterogeneity and provide test-
able suggestions for novel genes that may influence the
development of the hippocampal and visual system, which
may influence the development of the PCA phenotype rela-tive to other syndromes. If confirmed in future studies, next
generation sequencing may be useful in determining
whether these findings might be underpinned by rare variants
with large effect sizes. More broadly, genetic investigation
of well-phenotyped AD variants may provide important in-
sights into disease biology in typical AD.Acknowledgments
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1. Systematic review: Reviewing the literature for pub-
lications investigating the genetics of posterior
cortical atrophy (PCA), there is conflicting evidence
for the role of APOE in the PCA variant of Alz-
heimer’s disease AD), and limited evidence for the
more recently identified genetic risks for AD.
2. Interpretation: Through the establishment of an inter-
national consortium to create the largest study
exploring the genetics of PCA to date, we demon-
strate that (1) APOE is a risk factor for PCA but con-
fers a smaller risk than for typical AD; (2) some of
the genetic risks for typical AD are also associated
with PCA risk; and (3) nominate three novel risk
loci for PCA.
3. Future directions: These data provide clear directions
and testable hypotheses for future studies, including
(1) the establishment of a replication cohort and (2)
investigation of the identified genes as factors influ-
encing selective vulnerability in AD.References
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